Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies

Key facts

Sponsor

Longboard Pharmaceuticals

Principal Investigator

Dennis J Dlugos, MD

Children's Hospital of Philadelphia

Intervention

LP352(drug)

Enrollment

52 enrolled

Eligibility

12-65 years · All sexes

Timeline

2022 – 2023

Study locations (30)

• University of Arizona - Health Sciences Center, Tucson, Arizona, United States
• Arkansas Children's Hospital, Little Rock, Arkansas, United States
• Rancho Los Amigos National Rehabilitation Center (RLANRC), Downey, California, United States
• Children's Hospital of Orange County, Orange, California, United States
• University of California San Francisco, San Francisco, California, United States
• Northwest Florida Clinical Research Group, Gulf Breeze, Florida, United States
• University of Miami, Miami, Florida, United States
• Advent Health Orlando, Orlando, Florida, United States
• Research Institute of Orlando, Orlando, Florida, United States
• University of South Florida, Tampa, Florida, United States
• Hawaii Pacific Neuroscience, Honolulu, Hawaii, United States
• Consultants in Epilepsy and Neurology, Boise, Idaho, United States
• Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
• Mid-Atlantic Epilepsy and Sleep Center, Bethesda, Maryland, United States
• Spectrum Health, Grand Rapids, Michigan, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Infantile epileptic-dyskinetic encephalopathy

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE3NCT06908226
  A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
  Longboard Pharmaceuticals

See all trials for Infantile epileptic-dyskinetic encephalopathy →